Fresenius Medical Care AG

Fresenius Medical Care AG(FMS)股票分析

$22.170

+0.040 (+0.18%)收盤時

Loading chart…
最高
22.380
開盤
22.280
成交量加權均價
22.22
成交量
620.94K
市值
11.25B
最低
22.105
成交金額
13.80M
企業價值/稅息折舊攤銷前利潤(TTM)
5.83

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

AI 分析 of Fresenius Medical Care AG (FMS)

持有

Fresenius Medical Care AG is currently trading at $22.17, with a forward P/E of 8.58, indicating it is undervalued compared to its earnings potential. However, the stock has seen a 5.27% increase over the last five days, suggesting some positive momentum. The main risk is its declining U.S. same-market treatment growth, which is down 0.9%, indicating potential challenges ahead.

估值指標

Fresenius Medical Care AG(FMS)目前預期本益比為 8.58,5 年平均預期本益比為 12.82。

預期本益比

低估
5 年均值 P/E
12.82
目前P/E
8.58
高估
16.45
低估
9.19

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
7.18
目前EV/EBITDA
5.83
高估
8.13
低估
6.24

預期股價營收比

合理
5 年均值 P/S
0.63
目前P/S
0.59
高估
0.76
低估
0.51

持有 FMS 的大戶

P

Pzena Investment Management, Inc.

+ 持有FMS

+6.58%

3個月報酬率

C

Cobas Asset Management, SGIIC, SA

+ 持有FMS

+5.86%

3個月報酬率

F

Fresenius SE & Co. KGaA

+ 持有FMS

-7.89%

3個月報酬率

事件時間軸

2026-10-07 (ET)

11:30:00

Fresenius Medical Trading Resumes

11:00:00

Fresenius Medical Trading Halted, News Pending

11:00:00

Fresenius Medical Appoints Shervin Korangy as CEO

2026-05-28 (ET)

07:10:00

Fresenius Medical Care Launches €1B Share Buyback Program

2026-05-26 (ET)

07:10:00

Fresenius Medical Care Plans €1B Share Buyback

資訊

FMS 常見問題 —— 由 Alphio AI 解答

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.

Fresenius Medical Care AG is currently trading at $22.17, with a forward P/E of 8.58, indicating it is undervalued compared to its earnings potential. However, the stock has seen a 5.27% increase over the last five days, suggesting some positive momentum. The main risk is its declining U.S. same-market treatment growth, which is down 0.9%, indicating potential challenges ahead.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易